General Healthy(605186)2022-11-17 14:24Group 1: Company Performance and Recovery - The company resumed full operations on June 1, 2022, after being approved as a second batch of companies for resumption in Shanghai [3] - The overall business performance remained stable despite the impact of the COVID-19 pandemic [3] - The company has implemented refined management strategies to adapt to the pandemic situation [4] Group 2: Market Position and Client Base - The company has implemented intelligent drug management projects in over 700 hospitals across 29 provinces, with more than half of the top 100 hospitals in China as clients [3] - The company focuses on the pharmaceutical intelligent management sector and has a strong market presence in economically developed coastal regions, particularly in first and second-tier cities [4] Group 3: Future Strategy and Business Development - In 2022, the company aims to enhance product development and market expansion while optimizing production and management efficiency [4] - The company plans to explore the "to-G" market and increase its market share in the retail pharmaceutical sector [4] - The company has a strategic layout for the retail market and aims to penetrate lower-tier medical service institutions [4]